The same principle has formed the basis of a recent trial done by Duffy et al. (2017), where they evaluated 19 patients of advanced HCC to understand the clinical response of combining ablation with anti-CTLA-4 (tremelimumab). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.